Ask AI

Resolving Unmet Needs in CMVi: Contemporary Strategies for Improved HCT Outcomes

Cytomegalovirus infection (CMVi) remains a major source of morbidity and mortality in hematopoietic cell transplant (HCT) recipients. With these activities, learn to effectively identify and monitor high-risk patients, individualize treatment to minimize adverse effects, and optimize therapy for treatment-refractory CMV in post-HCT settings. 

Share

Program Content

Events

Activities

Contemporary CMV Management Slides
Optimizing Transplant Outcomes Through Contemporary CMV Management: Strategies to Address Clinical Challenges in Treatment of Refractory or Resistant Disease
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with ProCE, LLC.

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Partners

ProCE, LLC

ProCE Banner